Received: 8 April 2021
Accepted: 21 December 2021
First Online: 6 January 2022
: This study, sponsored by Oncodesign, was authorized by the French Health Agency (ANSM- <i>Agence Nationale de la Sécurité du Médicaments et des produits de santé</i>”, IDRB n°: 2017-A02018-45) in 07032017, and by the French Ethical Research Committee (CPP- “<i>Comité de Protection des Personnes, Nord Ouest IV Lille</i>”, CPP 17–61) in 09172020 for a period of 6 years. The clinical trial has been registered at ClinicalTrials.gov with the identifier NCT04548960 on September 15<sup>th</sup> 2020. Participants must provide informed consent in agreement with the Declaration of Helsinki. Subjects will be informed of the objectives of the project and the risks and benefits of the explorations to be carried out. None of the tests will pose risks that could endanger participant life. Confidentiality of participant data will be guaranteed at all times in agreement with the CNIL MR01 reference methodology registered for ONCODESIGN with the identifier 2114192v0 on October 27<sup>th</sup> 2017.
: This section is not applicable.
: N. GIRARD: Research/Grant Support: MS, AstraZeneca, Abbvie, Amgen, Boehringer-Ingelheim, EliLilly, Hoffmann-La Roche, Janssen, Merck, MSD, Novartis, Pfizer, Sivan, Trizell.Consultative Services: BMS, AstraZeneca, Abbvie, Amgen, Boehringer-Ingelheim, EliLilly,Hoffmann-La Roche, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi, Sivan.